drugset
drugset / Trial / NCT06627231

Mass Balance Clinical Trial With TEV-56286

NCT06627231 ↗

Phase 1 Completed 8 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Mass balance clinical trial with TEV-56286

Timeline

Start
2024-10-08
Primary completion
2024-11-29
Completion
2024-11-29

Drugs

EvaluationDrugModalityDoseRoute
Subject TEV-56286 Unknown — Oral

Indications

No indication recorded.